Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kanghong Pharma Gains CFDA Approval for China’s First Innovative MAb

publication date: Dec 20, 2013
Chengdu Kanghong Pharmaceutical Group was granted CFDA approval for Compaq Sipp ophthalmic injection (conbercept), a novel treatment for wet age-related macular degeneration. The drug is the first innovative, China-developed monoclonal antibody to gain regulatory approval, a significant milestone. The company believes its drug offers significant advantages over existing western MAbs such as Roche/Genentech’s similar drug, which is marketed as Avastin and Lucentis, giving conbercept the potential to become a blockbuster. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital